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minutes at teaching hospitals and 175 minutes at non-teaching hospitals. There 
were significant variations in duration of routine ED visits across race groups at 
teaching and non-teaching hospitals. The risk-adjusted results show that the 
mean duration of routine ED visits for black/African American and Asian 
patients when compared to visits for white patients was shorter by 10.0 and 3.4 
percent, respectively, at teaching hospitals; and longer by 3.6 and 13.8 percent, 
respectively, at non-teaching hospitals. Hispanic patients experienced 8.7 
percent longer ED stays when compared to white patients at non-teaching 
hospitals. CONCLUSIONS: There is significant racial disparity in the duration of 
routine ED visits, especially in non-teaching hospitals where non-white patients 
experience longer ED stays compared to white patients. The variation in duration 
of routine ED visits at teaching hospitals when compared to non-teaching 
hospitals was smaller across race groups.  
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FOR SURGICAL PROCEDURES AT NATIONAL, REGIONAL AND HOSPITAL  
LEVEL  
Velleca M1, Petrarca G2, Perrone F1 
1Johnson & Johnson Medical, Pomezia (RM), Italy, 2Centro Studi Assobiomedica, Milano, Italy  
OBJECTIVES: The Italian National Health Service (Servizio Sanitario Nazionale-SSN) 
is structured on two levels: the national and regional level. The national 
government defines the benefits package (essential levels of care, livelli essenziali 
di assistenza-LEA) to which citizens are constitutionally entitled and which each 
Regional Health Service (Servizio Sanitario Regionale-SSR) is responsible for. Since 
1997 the regions have been fully autonomous in organizing and managing their 
SSR, including the definition of DRG tariffs for hospital admissions. The aim of 
this study is compare the regional differences among tariffs for the main surgical 
DRGs of each Major Diagnostic Category (MDC). METHODS: In order to identify 
the surgical DRGs with the highest volumes for each MDC, we used the dataset 
of admissions registered in 2010 by all hospitals (DRG version 24 ICD9-CM), 
published by the Italian Department of Health (Ministero della Salute), and we 
analyzed the variability among tariffs by calculating their average and standard 
deviations (the extra-reimbursement has not been considered). RESULTS: 
Average tariffs were calculated starting from the standard regional tariff for each 
DRG. Comparing the first 10 DRGs, we identified a variation in the average tariff 
which rose from -1.8% to +22.6% and a standard deviation with a minimum of 
425€ and a maximum of 1443€. Further complexity is given by the intra-regional 
variation by type of hospital, where we observed a variation inside the same 
region of 82% for the same DRG. CONCLUSIONS: The SSN is characterized by a 
high variability of regional DRG tariffs, also inside the regions. Moreover in Italy 
there is not a defined procedure to update the classification of DRGs and the 
related tariffs. Therefore there is a need to establish a systematic periodical 
review, which should involve all the different stakeholders of SSN, and to share 
data updated with them about the volume of admissions.  
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OBJECTIVES: The aim of our study was to investigate the financial effects of 
switching from the so-called performance volume limit (PVL) to degressive 
financing method in the Hungarian DRG-based hospital financing. METHODS: 
The data in our analysis were derived from the nationwide administrative 
dataset of the National Health Insurance Fund Administration (OEP), the only 
health care financing agency. We examined mainly the period between 2009 and 
2012. The difference in hospital reimbursement between the preannounced DRG 
reimbursement rate and degressive cap (upper ceiling) was calculated both on 
national level and in the case of the Clinical Center of the University of Pécs. 
RESULTS: The ratio of partially paid [based on preannounced performance base-
fee (PPBF) or performance volume limit (PVL) financing method] active inpatient 
cost-weights to total cost-weights varied extremely between 2009-2012. In the 
case of PPBF financing in 2009, 25-30% of the total national performance fell 
under floating fee structure, resulting in a monthly change in the monetary 
(Hungarian Forint, HUF) value of a DRG cost-weight. In the case of degressive PVL 
from 2011 onwards, one to seven percent of the national performance fell in the 
degressive zone, with a prefixed value of HUF 45,000/cost-weighs. For the Clinical 
Centre of the University of Pécs, this partial reimbursement resulted in a large 
financial deficit in 2009, when PPBF was applied. In 2010 and 2011, the deficit of 
the University of Pécs lessened to some extent compared to 2009; however, it 
was still rather high (HUF 1.46 and HUF 1.3 billion, respectively). Due to partial 
health insurance reimbursement, the University of Pécs realized HUF 8.1 billion 
revenue losses between 2004 and 2012. CONCLUSIONS: Application of 
preannounced performance base-fee rendered institutional financing nearly 
incalculable. Renewed introduction of degressive performance volume limit in 
2011 made institutional financing more calculable; however, it failed to entirely 
stop source withdrawal.  
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OBJECTIVES: The recent reforms and policy changes have increased the cost 
pressures on all health care stakeholders, including clinical experts. In the past, 
clinical guidelines were developed independent of cost or economic 
considerations. However, increasingly, more clinical guidelines are mentioning 
cost concerns and referring to economic data in new recommendations. The 
objective of this study was to analyze trends in the use of health economic 
information for developing clinical guidelines. METHODS: To understand trends 
in use of health economic information we conducted targeted search for clinical 
guidelines, expert recommendations, and consensus statements with specific 
mention of “cost” or “economic” or related terms. A systematic literature search 
was undertaken for the databases Pubmed, Google Scholar and Cochrane. The 
guidelines published between 2003-2012 were included. For guidelines which 
met the search criteria, data was collected for the name of the authors, 
indication, year of publication, country/region, and context of use of 
cost/economic evidence. RESULTS: Sixteen clinical guidelines published between 
2003-2012 met the inclusion criteria for specific mention of cost/economic 
evidence. More than 50% of these guidelines were published between 2006-2012. 
For indication, 3 out of 16 guidelines were for diabetes, while the rest were for 
different indications. In these16 guidelines “cost effectiveness” was mentioned 
14 times, either referencing cost-effectiveness data or to mention the importance 
of such data for selecting treatment options. The guidelines commonly cite high 
cost of disease or high economic burden as one of the considerations for 
developing new recommendations (11 out of 16). Another term that was 
commonly used by these guidelines was “cost-benefit,” which was mentioned 5 
times in these guidelines. Notably, QALY was rarely mentioned (1 out of 16 
times) in these guidelines. CONCLUSIONS: This analysis suggests that some 
clinical experts groups are increasingly showing willingness to use and 
incorporate health economic information for developing new recommendations.  
 
HEALTH CARE USE & POLICY STUDIES – Drug/Device/Diagnostic  
Use & Policy 
 
PHP10  
ANALYSIS OF THE WAXMAN-HATCH ACT PHARMACEUTICAL PATENT 
EXTENSIONS (1984-2012)  
Bin Sawad AH1, Alshahrani AM1, Seoane-Vazquez E2, Rodriguez-Monguio R3 
1Massachusetts College of Pharmacy and Health Sciences University, Boston, MA, USA, 2MCPHS 
University, Boston, MA, USA, 3University of Massachusetts, Amherst, MA, USA  
OBJECTIVES: The Drug Price Competition and Patent Term Restoration Act of 
1984 (Waxman- Waxman Act - WHA) established a patent extension system that 
allows sponsors of new drugs (NDAs) and biologic applications (BLAs) approved 
by Food and Drug Administration (FDA) to recover part of the patent time 
dedicated to clinical trials and to the FDA drug review process. The maximum 
extension is 5 years and the effective patent life from approval to patent 
expiration cannot exceed 14 years. We assessed the characteristic of drugs and 
biologics that had a patent extension in the period 1984-2012 and examined the 
patent life timeline from clinical trials to regulatory review, and from marketing 
authorization to patent expiration (i.e. effective patent life). METHODS: Data 
were derived from the FDA, the US Patent and Trademark Office, and the US 
Federal Register. Descriptive analyses were performed. T-test was used to assess 
differences in averages. Significant level was set at 0.05. RESULTS: The USPTO 
listed 499 pharmaceuticals with patent extensions in the study period; 453 NDAs 
(90.8%), 38 BLAs (7.6%), and 9 vaccines (1.8%). Drug regulatory and patent 
information was available for 323 pharmaceuticals (287 NDA, 32 BLA and 4 
vaccines). The average±stdev patent extension was 2.7±1.4 years (median=2.2 
years; 95% CI=2.62.8). The extension was longer for vaccines (3.7±1.3 years) than 
for NDAs (2.7±1.4 years) and BLAs (2.4±1.5 years). The average clinical trials time 
was 5.9±3.1 years, being similar for NDAs, BLAs and vaccines. The average FDA 
review time was 1.7±1.3 years (higher for vaccines 2.6±2.5 years). The average 
length of the effective patent life was 8.7±7.0 years without patent extensions 
and 11.7±6.8 years after the extensions. CONCLUSIONS: A large number of 
pharmaceuticals were granted patent extensions in the US. The WHA 
significantly increased the effective patent life of pharmaceuticals.  
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OBJECTIVES: A budget impact analysis(BIA) is a useful tool for a health care 
decision maker in estimating the financial impact of the new technology. In 
Korea, the content and presentation of results of the BIA have been proposed but 
detailed guidance on methods for BIA are not yet available. To evaluate the 
international landscape of BIA guidance, we compared guidelines of BIA outside 
of Korea. METHODS: A literature review was performed. Research for guidelines 
was based on data published in latest official papers or reports from ISPOR and 
national institutes in Canada, Ireland, and Poland. RESULTS: In all guidelines, 
the recommended perspective was that of public purchaser. A time horizon of 2-
5 years was considered to be desirable. It was stated that data on a technology 
and its use should be included in BIA, which is helpful for decision makers. 
Published guidelines provided a similar description of target population, but it 
was different whether or not off-label usage of drugs was included in 
assumption of population size. The approaches to measurement and evaluation 
of costs varied in different regions. The costing included direct costs associated 
with the technology in four guidelines but items of other costs were specified 
